Characterization of 2,500 Patients with Heart Failure and Analysis of Their Optimal Medical Therapy: Insights from the AMERICCAASS Registry.

IF 3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Global Heart Pub Date : 2025-03-11 eCollection Date: 2025-01-01 DOI:10.5334/gh.1418

Alex David Sotomayor-Julio, Sebastián Seni-Molina, Juliana María Gutiérrez-Posso, Juan Andrés Muñoz-Ordoñez, Valeria Azcárate-Rodríguez, Hoover O León-Giraldo, Eduardo R Perna, Víctor Rossel, Daniel Quesada-Chaves, Mario Speranza, Mark H Drazner, Walter Alarco, Alexander Romero-Guerra, Gabriel Frago, Daniela García Brasca, Álvaro Mauricio Quintero-Ossa, Javier Galeano Figueredo, Milton Lubeck Herrera, Antonella A Ferrer, Ruddy Miguel García-Safadit, Freddy Pow-Chon-Long, Felix Nunura Arrese, Kwame van der Hilst, Silvia Carolina Lazo-Majano, Elisabeth Ashley Hardin, Orlando David Fernández-Flores, Gabriela Ormaechea-Gorricho, Luis Felipe Anhuaman-Atoche, Annia María Carrero-Vásquez, Andrés Ulate Retana, Pablo Hurtado Nuñez, Emilio Samael Peralta-López, Juan Esteban Gómez-Mesa

{"title":"Characterization of 2,500 Patients with Heart Failure and Analysis of Their Optimal Medical Therapy: Insights from the AMERICCAASS Registry.","authors":"Alex David Sotomayor-Julio, Sebastián Seni-Molina, Juliana María Gutiérrez-Posso, Juan Andrés Muñoz-Ordoñez, Valeria Azcárate-Rodríguez, Hoover O León-Giraldo, Eduardo R Perna, Víctor Rossel, Daniel Quesada-Chaves, Mario Speranza, Mark H Drazner, Walter Alarco, Alexander Romero-Guerra, Gabriel Frago, Daniela García Brasca, Álvaro Mauricio Quintero-Ossa, Javier Galeano Figueredo, Milton Lubeck Herrera, Antonella A Ferrer, Ruddy Miguel García-Safadit, Freddy Pow-Chon-Long, Felix Nunura Arrese, Kwame van der Hilst, Silvia Carolina Lazo-Majano, Elisabeth Ashley Hardin, Orlando David Fernández-Flores, Gabriela Ormaechea-Gorricho, Luis Felipe Anhuaman-Atoche, Annia María Carrero-Vásquez, Andrés Ulate Retana, Pablo Hurtado Nuñez, Emilio Samael Peralta-López, Juan Esteban Gómez-Mesa","doi":"10.5334/gh.1418","DOIUrl":null,"url":null,"abstract":"Introduction: Heart failure (HF) is a leading cause of hospitalization and mortality worldwide, emphasizing the critical role of optimal medical therapy (OMT) in improving patient outcomes. Despite extensive research, most scientific evidence regarding HF is gathered and studied in developed countries, leaving substantial knowledge gaps regarding HF in Latin America and the Caribbean.Objective: To characterize the sociodemographic and clinical profiles of HF patients and to assess their adherence to OMT in the Americas.Methods: The AMERICCAASS Registry is a prospective, observational, multicenter study, including patients aged 18 and older, both hospitalized and ambulatory, and diagnosed with HF. Sociodemographic and clinical data were collected from the first 2,500 patients to characterize the study population. Adherence to OMT was subsequently evaluated according to left ventricular ejection fraction (LVEF).Results: Among the 2,500 patients in the study, 36% were hospitalized and 64% were ambulatory. The median ages of the patients were 66.9 (hospitalized) and 66.3 years (ambulatory). Males made up 60.8% of hospitalized and 59.3% of ambulatory patients. The majority had HF with reduced LVEF (≤40%): 60.7% for hospitalized and 58.5% for ambulatory. The New York Heart Association (NYHA) functional class II predominated among ambulatory patients (67.9%), while NYHA functional class III predominated among hospitalized patients (46.6%). Only 21% of patients with reduced LVEF were receiving quadruple therapy, whereas 12.3% of patients with mildly reduced LVEF (41-49%) were on this treatment.Conclusion: The findings demonstrate that the sociodemographic and clinical profiles of HF patients in the Americas are broadly consistent with international reports. However, the low use of OMT observed in this population underscores gaps in adherence to current guidelines. These results highlight the need for targeted strategies to improve pharmacological treatment adherence to optimize health outcomes in this region.","PeriodicalId":56018,"journal":{"name":"Global Heart","volume":"20 1","pages":"27"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11908427/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5334/gh.1418","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Heart failure (HF) is a leading cause of hospitalization and mortality worldwide, emphasizing the critical role of optimal medical therapy (OMT) in improving patient outcomes. Despite extensive research, most scientific evidence regarding HF is gathered and studied in developed countries, leaving substantial knowledge gaps regarding HF in Latin America and the Caribbean.

Objective: To characterize the sociodemographic and clinical profiles of HF patients and to assess their adherence to OMT in the Americas.

Methods: The AMERICCAASS Registry is a prospective, observational, multicenter study, including patients aged 18 and older, both hospitalized and ambulatory, and diagnosed with HF. Sociodemographic and clinical data were collected from the first 2,500 patients to characterize the study population. Adherence to OMT was subsequently evaluated according to left ventricular ejection fraction (LVEF).

Results: Among the 2,500 patients in the study, 36% were hospitalized and 64% were ambulatory. The median ages of the patients were 66.9 (hospitalized) and 66.3 years (ambulatory). Males made up 60.8% of hospitalized and 59.3% of ambulatory patients. The majority had HF with reduced LVEF (≤40%): 60.7% for hospitalized and 58.5% for ambulatory. The New York Heart Association (NYHA) functional class II predominated among ambulatory patients (67.9%), while NYHA functional class III predominated among hospitalized patients (46.6%). Only 21% of patients with reduced LVEF were receiving quadruple therapy, whereas 12.3% of patients with mildly reduced LVEF (41-49%) were on this treatment.

Conclusion: The findings demonstrate that the sociodemographic and clinical profiles of HF patients in the Americas are broadly consistent with international reports. However, the low use of OMT observed in this population underscores gaps in adherence to current guidelines. These results highlight the need for targeted strategies to improve pharmacological treatment adherence to optimize health outcomes in this region.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Global Heart Medicine-Cardiology and Cardiovascular Medicine

CiteScore

5.70

自引率

5.40%

发文量

审稿时长

5 weeks

期刊介绍： Global Heart offers a forum for dialogue and education on research, developments, trends, solutions and public health programs related to the prevention and control of cardiovascular diseases (CVDs) worldwide, with a special focus on low- and middle-income countries (LMICs). Manuscripts should address not only the extent or epidemiology of the problem, but also describe interventions to effectively control and prevent CVDs and the underlying factors. The emphasis should be on approaches applicable in settings with limited resources. Economic evaluations of successful interventions are particularly welcome. We will also consider negative findings if important. While reports of hospital or clinic-based treatments are not excluded, particularly if they have broad implications for cost-effective disease control or prevention, we give priority to papers addressing community-based activities. We encourage submissions on cardiovascular surveillance and health policies, professional education, ethical issues and technological innovations related to prevention. Global Heart is particularly interested in publishing data from updated national or regional demographic health surveys, World Health Organization or Global Burden of Disease data, large clinical disease databases or registries. Systematic reviews or meta-analyses on globally relevant topics are welcome. We will also consider clinical research that has special relevance to LMICs, e.g. using validated instruments to assess health-related quality-of-life in patients from LMICs, innovative diagnostic-therapeutic applications, real-world effectiveness clinical trials, research methods (innovative methodologic papers, with emphasis on low-cost research methods or novel application of methods in low resource settings), and papers pertaining to cardiovascular health promotion and policy (quantitative evaluation of health programs.